A tumour-specific subtype of lung cancer, two to five times more common in East Asian patients and the reason a targeted drug class works dramatically better for some patients than others. This page holds one confirmed and one newly found inherited risk locus for it.
Lung adenocarcinoma is the most common form of lung cancer, and a substantial share of cases are driven by a mutation in the EGFR gene — a mutation acquired within the tumour itself over a person's lifetime, not inherited. That distinction matters clinically: EGFR-mutant tumours often respond dramatically to a class of targeted drugs that tumours without the mutation do not, which is why testing a tumour for it is now routine. The mutation is also unevenly distributed by ancestry: it appears in roughly 30–50% of lung adenocarcinomas in East Asian patients, against 10–20% in European or American patients.
The study behind this page did not ask what raises lung adenocarcinoma risk in general — that was already partly known. It asked whether inherited genetic risk specifically favours the acquisition of this EGFR-mutant subtype, on top of raising lung adenocarcinoma risk overall. In 3,173 Japanese patients with EGFR mutation-positive lung adenocarcinoma and 15,158 controls, with two further validation studies, the answer came back at least partly yes.
Four loci already known to raise overall lung adenocarcinoma risk in East Asian populations — near TERT, BTNL2, TP63 and BPTF — were re-discovered here specifically as risk factors for the EGFR-mutant subtype. This page holds the BPTF variant, rs7216064, among that confirmed group.
The study also found two new loci. One sits in the HLA class II region — part of the immune system's machinery for presenting molecular fragments to immune cells — with an odds ratio of 1.36, the strongest new signal. The other, held on this page, is rs2495239 near FOXP4, with an odds ratio of 1.19. FOXP4 is a transcription factor, and its region has also turned up in general lung cancer genetics elsewhere; finding it again here, specifically tied to the EGFR-mutant subtype, sharpens rather than contradicts that earlier signal.
An immune-region signal in a cancer defined by a tumour's own acquired mutation is a genuinely interesting juxtaposition: it suggests inherited variation in immune surveillance may influence which cells go on to acquire and tolerate this particular mutation, though the study itself does not settle the mechanism.
This page is about inherited common variants that shift the odds of developing this cancer subtype. It has nothing to do with the EGFR mutation itself, which is acquired within the tumour and tested for directly on a biopsy sample — not inferred from a person's own genome. The two are entirely separate questions: one is who is somewhat more likely to develop this cancer, the other is what to do about a tumour once it exists.
What actually matters for someone diagnosed with lung adenocarcinoma. Whether a tumour carries an EGFR mutation is determined by testing the tumour tissue itself, and that result — not anything on this page — decides whether EGFR-targeted therapy is an option. Nothing here substitutes for that tumour testing.
Smoking remains the dominant risk factor for lung cancer overall, though EGFR-mutant adenocarcinoma is notably more common in people who have never smoked than other lung cancer subtypes are. Neither the variants on this page nor smoking history changes how a diagnosed tumour is tested and treated — that rests on the tumour's own biology.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about EGFR Mutation-Positive Lung Adenocarcinoma comes down to these specific, well-studied positions — not a diagnosis.
Databases, guidelines and references
No. The EGFR mutation this page is named for is acquired within a tumour, not inherited, and is tested for directly on tumour tissue. The two variants here are inherited common variants that shift the odds of developing this cancer subtype — a different question entirely.
No. Whether a diagnosed tumour responds to EGFR-targeted therapy depends entirely on the tumour's own EGFR mutation status, determined by testing the tumour itself. Nothing on this page substitutes for that test.
It is a genuinely interesting and unresolved finding. The study's new HLA-region signal is the strongest one it found, and one interpretation is that inherited variation in immune surveillance influences which cells tolerate an EGFR mutation well enough for a tumour to develop — but the study does not establish the mechanism.
The study was conducted and validated entirely in Japanese cohorts, and EGFR-mutant lung adenocarcinoma itself is far less common outside East Asian populations. Whether these specific loci transfer to other ancestries has not been established here.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.